Genitourinary Cancer

Panel 20 - (INTERACTIVE) Brachytherapy Boost for Prostate Cancer: Magic Bullet or Risky Tool?

9/18/2019
11:15 AM - 12:30 PM
Location: Room W178

Session Type: Panel
1.25 AMA PRA Category 1 Credits™
1.5 MDCB Credits

This session will focus on the latest evidence on the benefits and harms of brachytherapy boost as part of a combination approach for high risk prostate cancer. This is a high profile topic based upon the results of ASCENDE-RT, which showed a marked improvement in biochemical progression free survival at the expense of higher GU toxicity, igniting debate among radiation oncologists. Presenters will highlight the evidence for brachytherapy boost and compare the evidence in support of alternative options. The panelists include both brachytherapy boost supporters and a speaker who interprets the recent clinical trials to not support brachytherapy boost, with the goal of providing a broad perspective rather than a debate format. Dr. Hoskin will review the current evidence for prostate brachytherapy, including his trial of prostate HDR brachytherapy boost. Dr. Spratt will provide a perspective on the urinary toxicity of prostate brachytherapy and the need to weigh that against the PSA failure free survival benefits. Dr. Krauss will provide an overview of various brachytherapy approaches in the combination and monotherapy settings and present emerging concepts in brachytherapy.

Learning Objectives:

Presentations:

Daniel Krauss, MD

Oakland University William Beaumont School of Medicine

Disclosure:
Employment
Beaumont Health

Presentation(s):

Send Email for Daniel Krauss


Assets

Panel 20 - (INTERACTIVE) Brachytherapy Boost for Prostate Cancer: Magic Bullet or Risky Tool?



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Panel 20 - (INTERACTIVE) Brachytherapy Boost for Prostate Cancer: Magic Bullet or Risky Tool?